A higher dose and shorter treatment time of a cornerstone tuberculosis (TB) drug has proven to be safe for patients, according to a clinical trial led by researchers at St George’s, University of London and results published in NEJM Evidence.
| Starting Tuition: | £55,500 |
|---|---|
| Location: | Large city |
| Total Enrollment: | 17,750 |
| Scholarship: | Upto 70% |